Tamoxifen (antiestrogen), aromatase inhibitors (estrogen withdrawal), and fulvestrant (direct targeting on the ERa receptor) are now used to treat ERa-positive breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.